Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaspar Broch

Showing results (41-50 of 97) with videos related to

Pageof 10
Sort By:
European Journal of Heart Failure|February 4, 2012
Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiologyKaspar Broch, Thor Ueland, Ståle H Nymo, et al.
Scientific Reports|March 20, 2024
No adverse association between exercise exposure and diffuse myocardial fibrosis in male endurance athletesKristoffer Andresen, Lars Gunnar Klæboe, Øyvind Haugen Lie, et al.
Atherosclerosis|January 22, 2026
Circulating B-cell activating factor in acute coronary syndromes - association with adverse outcomes and progression of heart failureThor Ueland, Geir Øystein Andersen, Sharanga Varathalingam, et al.
Journal of Cardiac Failure|July 10, 2017
Increased Secondary/Primary Bile Acid Ratio in Chronic Heart FailureCristiane C K Mayerhofer, Thor Ueland, Kaspar Broch, et al.
American Heart Journal|August 21, 2025
DAPAgliflozin for Renal protection in Heart Transplant recipients. Rationale and design of the randomized controlled DAPARHT trialStine Holmen, Olivier Manintveld, Kevin Damman, et al.
Plos One|March 4, 2014
The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trialKaspar Broch, Erik T Askevold, Erik Gjertsen, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 21, 2023
A man in his seventies with fatigue and renal failureMargrethe Flesvig Holt, August Flø, Vilde Bjørnø, et al.
Clinical Transplantation|May 24, 2020
Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trialKaspar Broch, Einar Gude, Kristjan Karason, et al.
International Journal of Cardiology. Heart & Vasculature|October 27, 2025
Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosisMargrethe Flesvig Holt, Annika E Michelsen, August Flø, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 22, 2024
Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trialEntela Bollano, Arne K Andreassen, Hans Eiskjaer, et al.
Pageof 10

Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
European Journal of Heart Failure|February 4, 2012
Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiologyKaspar Broch, Thor Ueland, Ståle H Nymo, et al.
Scientific Reports|March 20, 2024
No adverse association between exercise exposure and diffuse myocardial fibrosis in male endurance athletesKristoffer Andresen, Lars Gunnar Klæboe, Øyvind Haugen Lie, et al.
Atherosclerosis|January 22, 2026
Circulating B-cell activating factor in acute coronary syndromes - association with adverse outcomes and progression of heart failureThor Ueland, Geir Øystein Andersen, Sharanga Varathalingam, et al.
Journal of Cardiac Failure|July 10, 2017
Increased Secondary/Primary Bile Acid Ratio in Chronic Heart FailureCristiane C K Mayerhofer, Thor Ueland, Kaspar Broch, et al.
American Heart Journal|August 21, 2025
DAPAgliflozin for Renal protection in Heart Transplant recipients. Rationale and design of the randomized controlled DAPARHT trialStine Holmen, Olivier Manintveld, Kevin Damman, et al.
Plos One|March 4, 2014
The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trialKaspar Broch, Erik T Askevold, Erik Gjertsen, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|June 21, 2023
A man in his seventies with fatigue and renal failureMargrethe Flesvig Holt, August Flø, Vilde Bjørnø, et al.
Clinical Transplantation|May 24, 2020
Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trialKaspar Broch, Einar Gude, Kristjan Karason, et al.
International Journal of Cardiology. Heart & Vasculature|October 27, 2025
Increased dipeptidyl peptidase 4 in patients with concomitant transthyretin cardiac amyloidosis and severe aortic stenosisMargrethe Flesvig Holt, Annika E Michelsen, August Flø, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|July 22, 2024
Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trialEntela Bollano, Arne K Andreassen, Hans Eiskjaer, et al.
Pageof 10